Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Danish Nationwide Matched Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circadian rhythm of markers of bone turnover in patients with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: We describe real-world evidence (RWE) from the nationwide Swedish and Danish registries that provide important information on incidence and outcome in multiple myeloma (MM).

METHOD: First line treatment data on more than 10.000 MM patients from Denmark and Sweden between 2005-2018 are presented. Key results from research conducted within the Swedish and Danish myeloma registries are summarized, describing subgroups of patients with comorbidity, myeloma complications, and early relapse.

RESULTS: We show that national guidelines, generated on results from randomized clinical trials (RCTs) are rapidly implemented and improve overall survival (OS). We find that both the incidence of MM and the median age at diagnosis is higher in national registries compared to results from referral centres, indicating a more complete coverage. This highlights the need of validation of prognostic scoring systems and indices in e.g., SMM and high-risk MM in a real- world-population. We show that these subgroups are unlikely to be captured in RCTs with narrow inclusion and exclusion criteria, that they have worse survival, and are in need of new treatment approaches.

CONCLUSION: National registries that include all MM patients are an important source of knowledge on epidemiology, treatment and outcome with implications for the planning of MM care. Despite the introduction of new and better treatments, rapidly implemented in our countries, our registries uncover subgroups of patients that still have inferior outcome. Our RWE can help to identify important research questions to be studied in further clinical trials also in patients currently not included in RCTs.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume108
Issue number2
Pages (from-to)99-108
Number of pages10
ISSN0902-4441
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

    Research areas

  • Combined Modality Therapy/adverse effects, Denmark/epidemiology, Diagnosis, Differential, Disease Management, Humans, Incidence, Multiple Myeloma/diagnosis, Patient Outcome Assessment, Practice Guidelines as Topic, Public Health Surveillance, Registries, Sweden/epidemiology

ID: 79442287